{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:27:56Z","timestamp":1791563276796,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cisplatin-based chemotherapy remains a mainstay for the treatment of bladder cancer (BLCA); however, its clinical efficacy is frequently compromised by the emergence of chemoresistance, which leads to poor patient outcomes. Although known mechanisms\u2014such as alterations in drug efflux, DNA repair, and key signaling pathways\u2014have been implicated, they fail to fully explain the clinical complexity of cisplatin resistance, indicating that additional molecular drivers remain undiscovered. Keratin 14 (KRT14), an intermediate filament protein associated with aggressive BLCA subtypes, is consistently upregulated in cisplatin-resistant tumors, yet its precise mechanistic role in resistance remains unclear. In this study, we elucidate the functional contribution of KRT14 to cisplatin resistance in BLCA using patient-derived tissues, established cell lines, xenograft mouse models, and a suite of molecular interaction assays. Our results demonstrate that KRT14 is significantly upregulated in BLCA tissues, correlates with poor clinical prognosis, and functionally drives cisplatin resistance both in vitro and in vivo. Mechanistically, we identify a novel and direct interaction between KRT14 and the translation initiation factor eIF4H, specifically through the N-terminal Head domain of KRT14. This interaction modulates the association of eIF4H with the core eIF4F complex, thereby selectively promoting the translation of Acyl-CoA Oxidase 2 (ACOX2) mRNA through its 5\u2019 untranslated region. We further show that ACOX2 is essential for mediating the effects of KRT14 on lipid metabolism, cell proliferation, survival, and ultimately, cisplatin resistance. Collectively, our findings reveal that KRT14 contributes to chemoresistance in BLCA not only via its structural roles but also by directly regulating translational machinery through eIF4H, leading to upregulation of the metabolic enzyme ACOX2. The newly defined KRT14\u2013eIF4H\u2013ACOX2 axis orchestrates lipid metabolic reprogramming and cell survival, underscoring the KRT14\u2013eIF4H interface as a promising therapeutic target for overcoming cisplatin resistance in BLCA.<\/jats:p>","DOI":"10.1038\/s41419-025-08369-3","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T09:45:13Z","timestamp":1766569513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-1095","authenticated-orcid":false,"given":"Shenghua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-4067","authenticated-orcid":false,"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujia","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5349-1363","authenticated-orcid":false,"given":"Haowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"8369_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2024;85:17\u201331.","journal-title":"Eur Urol"},{"key":"8369_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07044-3","volume":"15","author":"WH Kao","year":"2024","unstructured":"Kao WH, Liao LZ, Chen YA, Lo UG, Pong RC, Hernandez E, et al. SPHK1 promotes bladder cancer metastasis via PD-L2\/c-Src\/FAK signaling cascade. Cell Death Dis. 2024;15:678.","journal-title":"Cell Death Dis"},{"key":"8369_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal R, Valderrama BP, Bellmunt J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol. 2024;21:8\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"8369_CR4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol. 2022;40:2013\u201322.","journal-title":"J Clin Oncol"},{"key":"8369_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1581-6","volume":"10","author":"X Long","year":"2019","unstructured":"Long X, Xiong W, Zeng X, Qi L, Cai Y, Mo M, et al. Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1\/ER\u03b2\/Bcl-2 signalling. Cell Death Dis. 2019;10:375.","journal-title":"Cell Death Dis"},{"key":"8369_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01928-0","volume":"40","author":"MS Selim","year":"2023","unstructured":"Selim MS, Kassem AB, El-Bassiouny NA, Salahuddin A, Abu El-Ela RY, Hamza MS. Polymorphic renal transporters and cisplatin\u2019s toxicity in urinary bladder cancer patients: current perspectives and future directions. Med Oncol. 2023;40:80.","journal-title":"Med Oncol"},{"key":"8369_CR7","doi-asserted-by":"publisher","first-page":"12488","DOI":"10.3390\/ijms232012488","volume":"23","author":"A Hol\u00ed\u010dkov\u00e1","year":"2022","unstructured":"Hol\u00ed\u010dkov\u00e1 A, Ro\u0161ka J, \u00d3r\u00e1sov\u00e1 E, Bruderov\u00e1 V, Palacka P, Jurkovi\u010dov\u00e1 D, et al. Response of the urothelial carcinoma cell lines to cisplatin. Int J Mol Sci. 2022;23:12488","journal-title":"Int J Mol Sci"},{"key":"8369_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03570-4","volume":"24","author":"Y Yan","year":"2024","unstructured":"Yan Y, Huang Z, Zhu Z, Wang Y, Cao X, Yang C, et al. IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. Cancer Cell Int. 2024;24:386.","journal-title":"Cancer Cell Int"},{"key":"8369_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s42003-024-07284-1","volume":"8","author":"Y Gong","year":"2025","unstructured":"Gong Y, Gao D, Shi Y, Fan G, Yu X, Yang E, et al. SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway. Commun Biol. 2025;8:36.","journal-title":"Commun Biol"},{"key":"8369_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07321-1","volume":"15","author":"Y Cao","year":"2024","unstructured":"Cao Y, Wang S, Ma J, Long M, Ma X, Yang X, et al. Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells. Cell Death Dis. 2024;15:931.","journal-title":"Cell Death Dis"},{"key":"8369_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41746-025-01560-y","volume":"8","author":"Z Bai","year":"2025","unstructured":"Bai Z, Osman M, Brendel M, Tangen CM, Flaig TW, Thompson IM, et al. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. npj Digit Med. 2025;8:174.","journal-title":"npj Digit Med"},{"key":"8369_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nature08908","volume":"463","author":"DA Fletcher","year":"2010","unstructured":"Fletcher DA, Mullins RD. Cell mechanics and the cytoskeleton. Nature. 2010;463:485\u201392.","journal-title":"Nature"},{"key":"8369_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.597835","volume":"8","author":"T Shimizu","year":"2020","unstructured":"Shimizu T, Fujii T, Sakai H. The relationship between actin cytoskeleton and membrane transporters in cisplatin resistance of cancer cells. Front Cell Dev Biol. 2020;8:597835.","journal-title":"Front Cell Dev Biol"},{"key":"8369_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2019.09.001","volume":"72","author":"S Werner","year":"2020","unstructured":"Werner S, Keller L, Pantel K. Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. Mol Aspects Med. 2020;72:100817.","journal-title":"Mol Aspects Med"},{"key":"8369_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.euf.2023.03.012","volume":"9","author":"S Schallenberg","year":"2023","unstructured":"Schallenberg S, Dragomir MP, Anders P, Ebner B, Volz Y, Eismann L, et al. Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer\u2014an extensive multiregional immunohistochemical analysis. Eur Urol Focus. 2023;9:788\u201398.","journal-title":"Eur Urol Focus"},{"key":"8369_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152\u201365.","journal-title":"Cancer Cell"},{"key":"8369_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","volume":"11","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang S, Sun H, Xu L. The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma. Cell Death Discov. 2025;11:186.","journal-title":"Cell Death Discov"},{"key":"8369_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10555-024-10170-1","volume":"43","author":"R Vishwa","year":"2024","unstructured":"Vishwa R, BharathwajChetty B, Girisa S, Aswani BS, Alqahtani MS, Abbas M, et al. Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?. Cancer Metastasis Rev. 2024;43:293\u2013319.","journal-title":"Cancer Metastasis Rev"},{"key":"8369_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","volume":"45","author":"AR Terry","year":"2024","unstructured":"Terry AR, Hay N. Emerging targets in lipid metabolism for cancer therapy. Trends Pharmacol Sci. 2024;45:537\u201351.","journal-title":"Trends Pharmacol Sci"},{"key":"8369_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","volume":"9","author":"JS Fleishman","year":"2024","unstructured":"Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024;9:97.","journal-title":"Signal Transduct Target Ther"},{"key":"8369_CR21","first-page":"2196","volume":"18","author":"I Kawahara","year":"2024","unstructured":"Kawahara I, Yoshino H, Fukumoto W, Arima J, Saito S, Li G, et al. Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Mol Oncol. 2024;18:2196\u2013211.","journal-title":"Mol Oncol"},{"key":"8369_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"8369_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-024-01749-9","volume":"9","author":"X Jia","year":"2024","unstructured":"Jia X, He X, Huang C, Li J, Dong Z, Liu K. Protein translation: biological processes and therapeutic strategies for human diseases. Signal Transduct Target Ther. 2024;9:44.","journal-title":"Signal Transduct Target Ther"},{"key":"8369_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41420-024-02185-y","volume":"10","author":"X Deng","year":"2024","unstructured":"Deng X, Yu YV, Jin YN. Non-canonical translation in cancer: significance and therapeutic potential of non-canonical ORFs, m(6)A-modification, and circular RNAs. Cell Death Discov. 2024;10:412.","journal-title":"Cell Death Discov"},{"key":"8369_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41594-023-01196-0","volume":"31","author":"J Brito Querido","year":"2024","unstructured":"Brito Querido J, Sokabe M, D\u00edaz-L\u00f3pez I, Gordiyenko Y, Fraser CS, Ramakrishnan V. The structure of a human translation initiation complex reveals two independent roles for the helicase eIF4A. Nat Struct Mol Biol. 2024;31:455\u201364.","journal-title":"Nat Struct Mol Biol"},{"key":"8369_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62681-0","volume":"14","author":"Y Mi","year":"2024","unstructured":"Mi Y, Dong M, Zuo X, Cao Q, Gu X, Mi H, et al. Genome-wide identification and analysis of epithelial-mesenchymal transition-related RNA-binding proteins and alternative splicing in a human breast cancer cell line. Sci Rep. 2024;14:11753.","journal-title":"Sci Rep"},{"key":"8369_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1086964","volume":"11","author":"A Montiel-D\u00e1valos","year":"2023","unstructured":"Montiel-D\u00e1valos A, Ayala Y, Hern\u00e1ndez G. The dark side of mRNA translation and the translation machinery in glioblastoma. Front Cell Dev Biol. 2023;11:1086964.","journal-title":"Front Cell Dev Biol"},{"key":"8369_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317846121","volume":"121","author":"YS Kim","year":"2024","unstructured":"Kim YS, Kimball SR, Piskounova E, Begley TJ, Hempel N. Stress response regulation of mRNA translation: implications for antioxidant enzyme expression in cancer. Proc Natl Acad Sci USA. 2024;121:e2317846121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8369_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.tips.2024.02.002","volume":"45","author":"S Chen","year":"2024","unstructured":"Chen S, Navickas A, Goodarzi H. Translational adaptation in breast cancer metastasis and emerging therapeutic opportunities. Trends Pharmacol Sci. 2024;45:304\u201318.","journal-title":"Trends Pharmacol Sci"},{"key":"8369_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217339","volume":"610","author":"MS Jeong","year":"2025","unstructured":"Jeong MS, Baek SW, Yang GE, Mun JY, Kim JA, Kim TN, et al. Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Lett. 2025;610:217339.","journal-title":"Cancer Lett"},{"key":"8369_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797.","journal-title":"EClinicalMedicine"},{"key":"8369_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117638","volume":"291","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu T, Li P, Xing Z, Mi L, He T, et al. Potential therapeutic targets of eukaryotic translation initiation factors in tumor therapy. Eur J Med Chem. 2025;291:117638.","journal-title":"Eur J Med Chem"},{"key":"8369_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41416-022-02058-0","volume":"128","author":"J Ren","year":"2023","unstructured":"Ren J, Yu H, Li W, Jin X, Yan B. Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer. Br J Cancer. 2023;128:232\u201344.","journal-title":"Br J Cancer"},{"key":"8369_CR34","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1073\/pnas.1505675112","volume":"112","author":"MC Velarde","year":"2015","unstructured":"Velarde MC, Demaria M, Melov S, Campisi J. Pleiotropic age-dependent effects of mitochondrial dysfunction on epidermal stem cells. Proc Natl Acad Sci USA. 2015;112:10407\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8369_CR35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"8369_CR36","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315\u201322.","DOI":"10.1038\/nature12965"},{"key":"8369_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11914","volume":"7","author":"G Papafotiou","year":"2016","unstructured":"Papafotiou G, Paraskevopoulou V, Vasilaki E, Kanaki Z, Paschalidis N, Klinakis A. KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis. Nat Commun. 2016;7:11914.","journal-title":"Nat Commun"},{"key":"8369_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00428-019-02593-x","volume":"475","author":"J Rebola","year":"2019","unstructured":"Rebola J, Aguiar P, Blanca A, Montironi R, Cimadamore A, Cheng L, et al. Predicting outcomes in non-muscle invasive (Ta\/T1) bladder cancer: the role of molecular grade based on luminal\/basal phenotype. Virchows Arch. 2019;475:445\u201355.","journal-title":"Virchows Arch"},{"key":"8369_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.trecan.2023.09.013","volume":"10","author":"L Duvivier","year":"2024","unstructured":"Duvivier L, Gerard L, Diaz A, Gillet JP. Linking ABC transporters to the hallmarks of cancer. Trends Cancer. 2024;10:124\u201334.","journal-title":"Trends Cancer"},{"key":"8369_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115851","volume":"217","author":"S Chandratre","year":"2023","unstructured":"Chandratre S, Olsen J, Howley R, Chen B. Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy. Biochem Pharmacol. 2023;217:115851.","journal-title":"Biochem Pharmacol"},{"key":"8369_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","volume":"51","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Arisa O, Peer CJ, Fojo A, Figg WD. PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin Oncol. 2024;51:19\u201324.","journal-title":"Semin Oncol"},{"key":"8369_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123228","volume":"359","author":"J Cao","year":"2024","unstructured":"Cao J, Chen S, Wang J, Fan X, Liu S, Li X, et al. Transcription factor PRRX1-activated ANXA6 facilitates EGFR-PKC\u03b1 complex formation and enhances cisplatin sensitivity in bladder cancer. Life Sci. 2024;359:123228.","journal-title":"Life Sci"},{"key":"8369_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"8369_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","volume":"26","author":"RJ Kishton","year":"2017","unstructured":"Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26:94\u2013109.","journal-title":"Cell Metab"},{"key":"8369_CR45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jhep.2016.11.005","volume":"66","author":"MJ Monte","year":"2017","unstructured":"Monte MJ, Alonso-Pe\u00f1a M, Briz O, Herraez E, Berasain C, Argemi J, et al. ACOX2 deficiency: an inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. J Hepatol. 2017;66:581\u20138.","journal-title":"J Hepatol"},{"key":"8369_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453\u20137.","journal-title":"Nature"},{"key":"8369_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2024.102325","volume":"87","author":"L Pradeau-Ph\u00e9lut","year":"2024","unstructured":"Pradeau-Ph\u00e9lut L, Etienne-Manneville S. Cytoskeletal crosstalk: a focus on intermediate filaments. Curr Opin Cell Biol. 2024;87:102325.","journal-title":"Curr Opin Cell Biol"},{"key":"8369_CR48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8:375.","journal-title":"Signal Transduct Target Ther"},{"key":"8369_CR49","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1038\/s41375-023-02043-3","volume":"37","author":"N Malik","year":"2023","unstructured":"Malik N, Hay J, Almuhanna HNB, Dunn KM, Lees J, Cassels J, et al. mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia. 2023;37:2414\u201325.","journal-title":"Leukemia"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08369-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:02:48Z","timestamp":1769536968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08369-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8369"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08369-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants were conducted in accordance with the principles of the Declaration of Helsinki and were reviewed and approved by the Ethics Committee of Huashan Hospital (Approval No. 22KN209). Written informed consent was obtained from all participants. All animal experiments were performed in compliance with the NIH Guide for the Care and Use of Laboratory Animals, and the protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the Fudan University Experimental Animal Center (Approval No. 2025-HSYY-552).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL"}}],"article-number":"134"}}